SLC2A1 and Alzheimer disease: Although the exact pathways involved are still unclear, future research between the GLP-1R agonists and GLUT1 or other molecules in BECs may provide more therapeutic targets for early interventions of BBB breakdown in neurodegenerative diseases especially AD (Figure 1).